Navigation Links
King Pharmaceuticals and Palatin Technologies Delay Immediate Plans for Phase 3 Clinical Program With Bremelanotide for Erectile Dysfunction
Date:8/30/2007

CRANBURY, N.J. and BRISTOL, Tenn., Aug. 30 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (Amex: PTN) and King Pharmaceuticals, Inc. (NYSE: KG) announced today that they have delayed plans for the initiation of Phase 3 clinical trials with bremelanotide, a first in class melanocortin agonist drug candidate, for the treatment of male erectile dysfunction (ED). The decision follows responses from representatives of the U.S. Food and Drug Administration (FDA), which raised serious concerns about the acceptable benefit/risk ratio to support the progression of the proposed program into Phase 3 studies for ED.

After reviewing the data generated in the Phase 1 and 2 studies, the FDA questioned the overall efficacy results and the clinical benefit of this product in both the general and diabetic ED populations, and cited blood pressure increases as its greatest safety concern. Though not supportive of the proposed Phase 3 studies for ED with bremelanotide, the FDA stated that it was amenable to proposals for a different drug development pathway, such as for a second-line therapy in non-responders to currently approved PDE-5 inhibitors.

"The safety of patients in our clinical program has always been our number one priority and we will work closely with the FDA, King, and our advisors to determine the next steps for the program," stated Carl Spana, Ph.D., President and Chief Executive Officer of Palatin.

Palatin and King plan to review the FDA comments in the overal
'/>"/>

SOURCE Palatin Technologies, Inc.; King Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Aug. 28, 2015  With the heroin epidemic in ... heights, Jacksonville -based Lakeview Health drug ... is helping to explain why fentanyl is causing a ... to 50 times more potent than pharmaceutical grade heroin ... heroin, the risk of death skyrockets. "Fentanyl ...
(Date:8/28/2015)... -- According to a new market research ... Type (Protein & Genetic Biomarkers) Profiling Technology (Proteomics, Genomics, ... - Global Forecast to 2020", published by MarketsandMarkets, The ... Million USD by 2020 at a CAGR of 13.9% ... Browse 191 Tables and 38 F ...
(Date:8/28/2015)... , Aug. 28, 2015 ... has announced the addition of the "12th ... and Production" report to their offering. ... of Biopharmaceutical Manufacturing Capacity and Production is the ... manufacturing organizations, current and projected future capacity and ...
Breaking Medicine Technology:Lakeview Health's Dr. Philip Hemphill Explains Why Heroin Addicts Are Now Dying of Fentanyl Overdoses 2Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 2Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 3Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 4Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 512th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production 2
... Percutaneous Administration (CUPID) Data Highlight Safety Profile and ... 26 Celladon Corporation today announced that results ... advanced heart failure, including Phase 1/2 data of ... Zsebo, PhD, President and CEO, Celladon Corporation and ...
... 26 Senesco Technologies, Inc. ("Senesco" or the "Company") ... mouse influenza survival studies that were conducted in Dr. William Scheld,s ... Mice treated with an siRNA against Senesco,s Factor 5A gene ... rate for mice that received no treatment or a control siRNA.A ...
Cached Medicine Technology:Celladon Corporation Announces Presentation of First-in-Human Gene Transfer to Treat Heart Failure at the 12th Annual Meeting of the American Society of Gene Therapy 2Senesco Announces H1N1 Influenza Survival Test Results in Mice 2Senesco Announces H1N1 Influenza Survival Test Results in Mice 3
(Date:8/30/2015)... ... August 31, 2015 , ... Avid collector Andrew Hawley ... Doors Shrine Auditorium concert posters. This hand colored artwork is one of the most ... Los Angles. Hawley states, "When the doors played the Shrine, the band was ...
(Date:8/30/2015)... ... August 31, 2015 , ... ChopChop Kids, the nonprofit publisher ... recently elected two new officers to serve on the organization’s Board of Directors ... and teaching kids to cook real food with their families and help continue ...
(Date:8/30/2015)... ... August 30, 2015 , ... Scientists in France say asbestos exposure ... of digestive cancers. Surviving Mesothelioma has just posted an article on the new research. ... Caen measured the cancer incidence among 2,024 French asbestos plant workers from 1978 to ...
(Date:8/30/2015)... ... August 30, 2015 , ... Nutritional Products International ( ... to Executive Assistant to CEO Mitch Gould for Nutritional Products International. Through ... goals. Kathleen graduated from Florida State University with a Bachelor of Science ...
(Date:8/29/2015)... ... August 29, 2015 , ... On Saturday, September 19, 2015, Diane ... Foundation (Meso Foundation) will present an educational program titled “Asbestos and Your Health.” ... through 9:30 PM (doors open at 6:45pm) at Calvary United Methodist Church, 16 E ...
Breaking Medicine News(10 mins):Health News:ChopChop Kids Appoints New Chair and Vice-Chair to Board of Directors 2Health News:ChopChop Kids Appoints New Chair and Vice-Chair to Board of Directors 3Health News:Researchers Say Mesothelioma Not the Only Cancer Linked with Asbestos Exposure, According to Surviving Mesothelioma 2Health News:NPI Appoints New Executive Assistant To CEO 2Health News:Mesothelioma Applied Research Foundation to Hold Educational Class About Asbestos and Mesothelioma Prevention 2
... likely woman was first infected with dangerous germ, , , WEDNESDAY, ... their food and more with their pets, but one thing ... is a drug-resistant staph infection. , However, according to a ... England Journal of Medicine , a German family appears to ...
... Public Understanding of a,21st Century Epidemic, ... of the,population, experts warn that Alzheimer,s disease ... and unsustainable burdens in,terms of health care ... lost to a devastating disease., (Photo: ...
... 2008, LANCASTER, Pa., March 12 Herley Industries,Inc. ... the second quarter,ended February 3, 2008., Net sales ... $34.7 million. Net loss for the period was approximately ... Company,s Chairman and CEO, will host a conference call,on ...
... 3 and Turmeric ... Supplement, LEXINGTON, ... the latest addition to their family of joint,relief products, which can be ... formula containing Omega 3 and,Turmeric for double strength joint relief., Over ...
... Caregivers were stressed, ate poorly, study found , , WEDNESDAY, March ... serious heart problem may raise your own risk of cardiac ... than 500 family members and others caring for a heart ... of the time were more likely to show psychological strain ...
... novel aerosol version of the most common tuberculosis ... an oral mist, offers significantly better protection against ... dose of the traditional injected vaccine, researchers report ... Academy of Sciences. , The aerosol vaccine -- ...
Cached Medicine News:Health News:Woman and Cat Shared 'Super Bug' 2Health News:Woman and Cat Shared 'Super Bug' 3Health News:New Tools Boost Alzheimer's Awareness 2Health News:New Tools Boost Alzheimer's Awareness 3Health News:Herley Reports Second Quarter Results 2Health News:Herley Reports Second Quarter Results 3Health News:Herley Reports Second Quarter Results 4Health News:Herley Reports Second Quarter Results 5Health News:Herley Reports Second Quarter Results 6Health News:Herley Reports Second Quarter Results 7Health News:Herley Reports Second Quarter Results 8Health News:Herley Reports Second Quarter Results 9Health News:Herley Reports Second Quarter Results 10Health News:The Makers of Conquer HA(TM) Launch All-Natural Double Strength Anti- Inflammatory Formula 2Health News:Caring for Heart Patients Can Strain Hearts 2Health News:Caring for Heart Patients Can Strain Hearts 3Health News:Inhaled tuberculosis vaccine more effective than traditional shot 2
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
... a monopolar cautery connector extending from the ... used for electrosurgery when properly attached to ... ,Ethicon Endo-Surgery provides disposable handheld instruments ... Our handheld instruments come in 5mm and ...
... The Featured Products ... at Mediflex and are ... modular in regular or ... come equipped with insulation, ...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
Medicine Products: